Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions-Reference-Cited by-同舟云学术

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions

Published:2023-09 Issue: Volume:30 Page:132-149
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Lam Norris,Finney Richard,Yang Shicheng,Choi Stephanie,Wu Xiaolin,Cutmore Lauren,Andrade Jorge,Huang Lei,Amatya Christina,Cam Margaret,Kochenderfer James N.^ORCID

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference57 articles.

1. Design and development of therapies using chimeric antigen receptor-expressing T cells;Dotti;Immunol. Rev.,2014

2. Designing chimeric antigen receptors to effectively and safely target tumors;Jensen;Curr. Opin. Immunol.,2015

3. CAR therapy: The CD19 paradigm;Sadelain;J. Clin. Invest.,2015

4. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors;Eshhar;Proc. Natl. Acad. Sci. USA,1993

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T cell therapy for autoimmune disease;Nature Reviews Immunology;2024-06-03

2. Alternative splicing for tuneable expression of protein subunits at desired ratios;mAbs;2024-04-22

3. Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia;Molecular Therapy - Methods & Clinical Development;2024-03

4. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain;Molecular Therapy;2023-12